$104.54
0.16%
NYSE, Nov 18, 09:34 am EST. Market open.
ISIN
US0028241000
Symbol
ABT

Abbott Laboratories Stock News

Positive
●
Market Watch
●
14 days ago
Investment newsletters' favorite Dividend Aristocrat stocks
Neutral
●
PRNewsWire
●
16 days ago
Late-breaking one-year VERITAS study results were presented at the Transcatheter Cardiovascular Therapeutics conference and simultaneously published in JACC: Cardiovascular Interventions; data show the device achieved high closure rates of the left atrial appendage (LAA) and a low incidence of stroke Abbott's Amulet 360™ LAA Occluder is a next-generation device designed to reduce the risk of st...
Neutral
●
PRNewsWire
●
17 days ago
SonicForce is an investigational coronary intravascular lithotripsy (IVL) system that uses acoustic pressure waves, similar to those used to break up kidney stones, to crack calcium in coronary arteries and restore blood flow The system is designed to bring purposeful innovation to treating complex coronary calcium, with longer treatment lengths, more pulses and enhanced catheter deliverability...
Neutral
●
PRNewsWire
●
20 days ago
CROWN-MV trial will evaluate the safety and effectiveness of investigational Cephea mitral valve replacement device Abbott's Cephea is designed to provide a new, minimally invasive option for treating mitral valve disease, the most common type of heart valve ailment 30-day early feasibility study results for Cephea will be presented at TCT 2026 ABBOTT PARK, Ill., Oct. 29, 2026 /PRNewswire/ -- A...
Neutral
●
PRNewsWire
●
23 days ago
Powered by whole-genome sequencing and MAESTRO * technology, the next-generation Oncodetect test takes a distinct approach to MRD, tracking up to 5,000 patient-specific variants with a limit of detection below one part per million under high-end inputs 1, 2, 3 The next-generation Oncodetect test builds on more than 20 years of trusted leadership in using genomic information to personalize cance...
Neutral
●
PRNewsWire
●
26 days ago
Beta-CORRECT study shows a 10.6-fold higher risk of recurrence, reinforcing the prognostic value of molecular residual disease (MRD) testing 1 Building on its leadership in colorectal cancer screening with the Cologuard ® test, Abbott is connecting innovations across the cancer care continuum, from early detection to post-treatment monitoring ABBOTT PARK, Ill., Oct. 23, 2026 /PRNewswire/ -- For...
Negative
●
WSJ
●
28 days ago
Abbott plans to separate its nutrition business into an independent company with about $8.5 billion in annual sales.

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today